Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company that counts Novo Nordisk Foundation as one of its biggest investors, raised $301.5 million in an upsized US initial public ...
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...
While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US ...
Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory ...
If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...
National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in ...
Debut Biotech, a company innovating new molecules, is partnering with Image Skincare to launch a new beauty product, CNBC has learned. The San Diego-based company uses biotechnology and artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results